{
  "pmcid": "PMC6289290",
  "title": "VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles",
  "description": "A study on triple combination therapy for cystic fibrosis patients",
  "studyType": "Randomized Control Trial",
  "participants": 29,
  "study_parameters": {
    "summary": "The use of VX-445-tezacaftor-ivacaftor to target Phe508del CFTR protein resulted in increased CFTR function in vitro and translated to improvements in patients with cystic fibrosis with one or two Phe508del alleles.",
    "study_type": {
      "content": "Randomized Control Trial",
      "explanation": "The study is described as a 'randomized, controlled, double-blind, dose-ranging, phase 2 trial'.",
      "quotes": [
        "randomized, controlled, double-blind, dose-ranging, phase 2 trial was conducted to evaluate tezacaftor–ivacaftor"
      ]
    }
  },
  "participant_info": {
    "content": "29 CF patients",
    "explanation": "The study included patients with cystic fibrosis with specific genetic mutations.",
    "quotes": [
      "patients heterozygous for the Phe508del CFTR mutation and a minimal-function mutation",
      "patients homozygous for the Phe508del CFTR mutation"
    ]
  },
  "study_design": {
    "content": "Phase 2 randomized controlled trial evaluating VX-445–tezacaftor–ivacaftor combination therapy",
    "explanation": "The study design focused on dose-ranging and safety evaluation of the triple combination therapy.",
    "quotes": [
      "randomized, controlled, double-blind, dose-ranging, phase 2 trial",
      "Primary end points were safety and absolute change in percentage of predicted FEV1"
    ]
  },
  "variant_annotations": {
    "rs113993960": {
      "annotation_type": "Functional Analysis",
      "haplotype": "rs113993960",
      "gene": "CFTR",
      "drugs": ["elexacaftor", "ivacaftor", "tezacaftor"],
      "sentence": "Genotype del/del are associated with increased transport of CFTR when exposed to elexacaftor, ivacaftor and tezacaftor.",
      "significance": "Significant"
    }
  }
}